Short-sellers think Exact Sciences’ (NASDAQ:EXAS) colon cancer screening test, Cologuard, will get further away from turning a profit when rules kick in next year that require Medicare to pay less for the test. They also argue that Cologuard’s advantages over competing screening methods aren’t as great as they appear and that trends suggest Exact Sciences’ growth is more the result of hefty spending on marketing than doctors’ interest in ordering the test.
